NBTX Nanobiotix Corp: רווח למניה אחת ב-12 החודשים האחרונים

The development of Nanobiotix S.A. (NBTX) is tied to regulatory approvals and the pursuit of capital. The year-over-year EPS (TTM) trend captures these financial fluctuations, where the -58.80 level serves as a critical benchmark. The integration of nanoparticles into standard therapy promises a steady revenue stream, while management's flexible strategy in partnership with a pharma behemoth increases the likelihood of successful clinical trials.
Nanobiotix Corp - פילוחים אנליטיים ומדדי מפתח (NBTX)

This indicator measures the dynamics of net earnings per share over a rolling year, neutralizing quarterly gaps and capturing the business's operational response to market changes. For Nanobiotix S.A. (NBTX), which depends on FDA/EMA approvals and currently lacks active patients, the YoY change in EPS on a rolling 12-month basis serves as a marker of financial stability during the pre-commercialization phase supported by J&J.